Pharmaguy™ is a Pharma Marketing Pundit & Critic, Blogger & Publisher of Pharma Marketing News
In this 4-minute audio snippet, Maureen Winigrad and John Griffith of Centric Infographics, give an update on the impact of the Managing Epilepsy & Seizures infographic campaign they launched in 2013 and introduce a new companion piece for the #Dare to Say SUDEP campaign.
You have to give kudos to the good doctors and policy makers of the American Medical Association for trying over the course of many to ban or in some way curtail direct-to-consumer drug ads by pharmaceutical companies. The latest effort focuses on drug price transparency in ads. Will it succeed where the other efforts have failed?
In this 4-minute audio snippet, Jerry Matczak, Community Manager for the Lilly Clinical Open Innovation Team, explains how the Internet, transparency, sharing innovation, and engaging patients in online communities can change how pharmaceutical companies do research.
In this 2.5-minute audio snippet, Pharmaguy presents data from Kantar Media that shows that the death of professional print pharma advertising has been greatly exaggerated. He gets into which companies and drugs have spent the most on journal advertising and summarizes a study of physician attitudes regarding these ads.
In this 5-minute audio snippet, Silja Chouquet, Owner at whydot GmbH, suggests that pharmaceutical companies apply resources and their brains to come up with a solution that helps people take their medication and use these insights to develop the next generation of treatments.
In this 5-minute audio snippet Pharmaguy discusses the absurdity of Rx drug names.
In this 3-minute audio snippet, Todd D. Clark, President of Value of Insight Consulting and the author of pharmahandbook and generichandbook, discusses a few ideas on how the pharmaceutical industry can avoid the slow-growth trap in the U.S. market.
Pharmaguy's Social Media Timeline
In this 2.5-minute audio snippet, Patricia Alves and Jaclyn Fonteyne, members of the Boehringer Ingelheim Social Media Team, talk about the working with legal-regulatory to plan TweetChats and what they consider to be the measures of success -- aka, return on investment -- for pharma TweetChats.